Citigroup Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by equities researchers at Citigroup from $795.00 to $750.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup’s price target would indicate a potential upside of 9.13% from the company’s current price.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Royal Bank of Canada reduced their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $687.27 on Tuesday. Regeneron Pharmaceuticals has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a market cap of $75.52 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 1.59 and a beta of 0.10. The company’s fifty day simple moving average is $724.48 and its 200 day simple moving average is $930.31. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC increased its position in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $127,489,000. KBC Group NV grew its position in shares of Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares during the period. Icon Wealth Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares during the period. Finally, State Street Corp grew its position in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.